Clinical Trials
11 trialsNCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT05475925 2026-04-17
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Dren Bio
Phase 1/2 Recruiting
NCT01787409 2025-12-30
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Mayo Clinic
Phase NA Active not recruiting
NCT04795869 2023-10-10
Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell Lymphoma
Northwestern University
Phase 2 Withdrawn
NCT01445535 2021-11-03
Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT02533700 2020-03-10
CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCL
Shandong Provincial Hospital
Phase 2 Unknown
NCT02652715 2019-11-15
Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Mayo Clinic
Phase NA Completed
NCT01746992 2017-11-14
CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Ruijin Hospital
Phase 4 Unknown
NCT00671112 2015-10-28
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00787527 2014-09-09
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00810576 2012-08-07
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma
M.D. Anderson Cancer Center
Phase 2 Terminated